For a patient with atrial fibrillation on rivaroxaban (Xarelto) who recently received a vascular stent and is on clopidogrel (Plavix) and aspirin (ASA), has a prior gastrointestinal bleed requiring transfusion, and now has lower‑leg patellar symptoms, what is the recommended duration of dual antiplatelet therapy and should aspirin be discontinued now?

Discontinue Aspirin Immediately and Continue Rivaroxaban Plus Clopidogrel

Given this patient's prior gastrointestinal bleed requiring transfusion and current triple therapy (rivaroxaban, clopidogrel, aspirin), you should discontinue aspirin immediately and continue rivaroxaban with clopidogrel alone for up to 6 months post-stent, then transition to rivaroxaban monotherapy.

Rationale for Early Aspirin Cessation

This patient represents a high bleeding risk scenario that mandates the shortest possible duration of triple therapy. The 2024 ESC Guidelines explicitly recommend early cessation of aspirin (≤1 week) after uncomplicated PCI in patients with atrial fibrillation requiring oral anticoagulation, particularly when bleeding risk is high 1. Your patient's prior GI bleed requiring transfusion definitively places her in the high bleeding risk category.

The most recent evidence strongly supports this approach:

• After uncomplicated PCI with concomitant OAC indication: Early aspirin cessation (≤1 week) followed by OAC plus clopidogrel for up to 6 months (not at high ischemic risk) or up to 12 months (high ischemic risk), then OAC alone 1

• When bleeding concerns prevail: Rivaroxaban 15 mg daily should be considered in preference to 20 mg daily for the duration of concomitant antiplatelet therapy 1

Specific Management Algorithm

Immediate Actions:

1. Stop aspirin now (assuming >1 week post-PCI)
2. Continue rivaroxaban - verify she's on 15 mg daily (not 20 mg) given the concomitant antiplatelet therapy 1
3. Continue clopidogrel 75 mg daily
4. Initiate proton pump inhibitor - this is a Class I recommendation for patients at increased GI bleeding risk receiving combined antithrombotic therapy 1

Duration Strategy:

For a vascular (peripheral) stent with high bleeding risk:

• Continue dual therapy (rivaroxaban + clopidogrel) for 1-6 months post-stent 1, 2
• Given her prior GI bleed, aim for the shorter end (1-3 months) unless there are high-risk stent characteristics 1, 2
• After dual therapy period: rivaroxaban monotherapy indefinitely for atrial fibrillation 1

Critical Considerations for This Patient

High Bleeding Risk Factors Present:

• Prior GI bleed requiring transfusion (most significant)
• Triple antithrombotic therapy
• Recent surgery (patellar procedure)

Assess Ischemic Risk:

The duration of clopidogrel depends on whether this was:

• Low ischemic risk (simple stent, stable disease): 1-3 months dual therapy 1, 2
• High ischemic risk (complex stenting, multiple stents, diabetes, prior MI): up to 6 months dual therapy 1, 2

Contact the interventionalist to clarify:

• Stent type (bare metal vs drug-eluting)
• Procedural complexity
• Whether this was for acute limb ischemia or stable disease

Common Pitfalls to Avoid

Do NOT:

• Continue triple therapy beyond 1 week in this high-bleeding-risk patient 1
• Use prasugrel or ticagrelor instead of clopidogrel with triple therapy 1
• Stop rivaroxaban (her stroke prevention for AF must continue lifelong) 1
• Use rivaroxaban 20 mg daily while on dual therapy - should be 15 mg 1

Do:

• Ensure PPI compliance (she had prior GI bleed) 1
• Monitor for any bleeding signs closely during first 3 months 2
• Restart clopidogrel immediately if temporarily held for patellar surgery 3
• Plan transition to rivaroxaban monotherapy after appropriate dual therapy duration 1

Regarding the Patellar Surgery

If the lower leg patellar surgery was recent and clopidogrel was held:

• Restart clopidogrel as soon as hemostasis achieved 3
• Clopidogrel can typically be held 5 days pre-operatively for procedures with bleeding risk 4
• The interruption should be as brief as possible given stent thrombosis risk 5, 4

Bottom Line

Your patient should be on rivaroxaban 15 mg daily plus clopidogrel 75 mg daily (without aspirin) for 1-6 months post-stent depending on ischemic risk assessment, then rivaroxaban alone. The prior GI bleed is the decisive factor pushing toward the shortest safe duration of dual therapy and immediate aspirin discontinuation. This approach balances stent thrombosis prevention against her substantial bleeding risk, prioritizing her survival and quality of life 1, 2.